Welcome to the Vanderbilt Health Affiliated Network

Of potential interest, favourable results with a reduction in systolic BP, albuminuria and progression of CKD were reported with the addition of a mineralocorticoid receptor antagonist (spironolactone) to standardized antihypertensive therapy, including ACEIs and ARBs [93-95]. ................
................